Clinical trials
Anemia clinical trials
Below are recruiting anemia clinical trials, each written for real people, not researchers. We’re tracking 269 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT07530380RecruitingEarly Phase 1
CAR T-cell therapy for treatment-resistant autoimmune hemolytic anemia
This trial tests a new type of cell therapy called UCAR T-cells, which are immune cells engineered to target and destroy the B cells causing your body to attack its own red blood cells. It's designed for patients whose autoimmune hemolytic anemia hasn't responded to at least 3 standard treatments.
HefeiAges 10 years+ - NCT06463236Recruiting
Study of anemia management in dialysis patients
This study is testing a new way to manage anemia (low red blood cells) in people on long-term dialysis. It aims to improve how doctors treat this common issue.
Chengdu, SichuanAges 18 years+ - NCT06466785RecruitingPhase 3
Study of Efepoetin Alfa for anemia in kidney dialysis patients
This study tests a new drug called Efepoetin Alfa to treat anemia in people with chronic kidney disease who are on dialysis. The goal is to see if it can safely raise red blood cell levels and reduce the need for other anemia treatments.
YerevanAges 18 years+ - NCT07667205Enrolling by invitationPhase 1
Liposomal vs. ferrous iron for preventing anemia in preterm babies
This trial compares two types of iron supplements—liposomal iron and ferrous iron—to see which works better at preventing iron deficiency anemia in premature infants. It aims to find a safer or more effective option for these fragile newborns.
CairoAges 2 weeks–3 weeks - NCT07136792Recruiting
New injection for anemia in dialysis patients taking roxadustat
This study tests a new once-monthly injection called pegmolesatide for anemia in people with kidney disease on dialysis who are already taking roxadustat. It aims to see if switching to this injection can keep hemoglobin levels stable and reduce the need for transfusions.
Beijing, Beijing MunicipalityAges 18–75 - NCT07741279Recruiting
Enarodustat for anemia in chronic kidney disease patients
This study tests a daily pill that helps people with chronic kidney disease and anemia make more red blood cells, which may reduce the need for other anemia treatments. It is for patients who are not on dialysis and do not plan to start dialysis or have a kidney transplant within the next six months.
Shanghai, Shanghai MunicipalityAges 18–85 - NCT07748533RecruitingPhase 1
CAR T-cell therapy for hard-to-treat autoimmune hemolytic anemia
This trial tests a new treatment using your own immune cells (CAR T-cells) to stop them from attacking your red blood cells. It is for people with autoimmune hemolytic anemia or Evans syndrome who have not improved after at least 3 previous treatments.
TianjinAges 18–75 - NCT07623161RecruitingPhase 3
Elritercept versus placebo for myelofibrosis anemia on ruxolitinib
This study tests whether a new drug called elritercept can help reduce the need for blood transfusions in adults with myelofibrosis (a bone marrow cancer) who are already taking ruxolitinib. The goal is to see if elritercept helps your body make more red blood cells naturally.
Glendale, CaliforniaAges 18 years+ - NCT07725497RecruitingPhase 2
Luspatercept for anemia from chronic kidney disease
This trial tests a drug called luspatercept to see if it can raise hemoglobin levels in people with anemia caused by chronic kidney disease. It's for those whose current treatments aren't working well or who cannot use them.
Basking Ridge, New JerseyAges 18 years+ - NCT07422480RecruitingPhase 3
Comparing elritercept to epoetin alfa for anemia in MDS needing transfusions
This trial tests a new drug called elritercept against a standard treatment, epoetin alfa, for people with a low-risk form of MDS who need regular blood transfusions for anemia. The goal is to see if elritercept works better to reduce the need for transfusions.
Gilbert, ArizonaAges 18 years+ - NCT07549698RecruitingPhase 1/Phase 2
CRISPR Gene Therapy for Immune Blood Disorders
This trial tests CTX112, a new CRISPR gene therapy that modifies your immune cells to treat severe immune thrombocytopenic purpura (ITP) or warm autoimmune hemolytic anemia (WAIHA) that hasn't responded to standard treatments. The goal is to see if it's safe and can help your body stop attacking its own blood cells.
Rochester, MinnesotaAges 18 years+ - NCT07476183RecruitingPhase 1
Testing APR-2020 for RPS19-deficient Diamond-Blackfan Anemia
This trial is testing a new treatment called APR-2020 for children and young adults with a specific type of Diamond-Blackfan Anemia (caused by a change in the RPS19 gene). The goal is to see if this treatment is safe, tolerable, and can help reduce the need for blood transfusions.
Stanford, CaliforniaAges 2–25 - NCT07714512RecruitingPhase 1/Phase 2
Anti-CD38 antibody for severe aplastic anemia not helped by other treatments
This study tests a new antibody drug (anti-CD38) for people with severe aplastic anemia that has not responded to or has come back after standard treatments. The goal is to see if this drug can help improve blood counts when other options have failed.
Tianjin, Tianjin MunicipalityAges 18 years+ - NCT07039422RecruitingPhase 2
Ianalumab re-treatment for ITP or wAIHA
This trial tests a re-treatment with ianalumab for people with ITP or warm-antibody autoimmune hemolytic anemia who previously benefited from the drug in an earlier Novartis study but then had their condition return after at least 2 years. It aims to see if a second course can help again.
Buenos AiresAges 18–100 - NCT07708714RecruitingPhase 1/Phase 2
Hydroxyurea study for teens with sickle cell anemia
This study tests how well a higher dose of hydroxyurea works for teenagers with sickle cell anemia living in areas where malaria is common. It looks at safety and how the treatment affects their daily lives.
KampalaAges 11–18 - NCT03050268Recruiting
Study of childhood cancer risk in families
This study looks at inherited (family) risk for childhood cancers, including families with early cancers or known cancer risk conditions. It may help researchers understand why some children get cancer and improve future risk detection and care.
Memphis, TennesseeAges Any age - NCT03173937RecruitingPhase 1/Phase 2
Cord blood transplant for severe aplastic anemia or MDS
This trial tests a special type of cord blood transplant using lab-grown stem cells to help the new blood-forming cells “take” sooner. It’s for people with severe aplastic anemia or certain MDS cases who have not responded well to standard immune-suppressing treatments.
Bethesda, MarylandAges 4–75 - NCT03520647RecruitingPhase 2
Haplo transplant for severe bone marrow failure using donor cells
This trial tests a stem cell transplant from a closely matched but not fully matched family donor (haploidentical), with chemotherapy after the transplant to help prevent graft-versus-host disease (GVHD). It may help people with severe aplastic anemia, certain MDS after transformation, or PNH when other treatments have not worked or are not available.
Bethesda, MarylandAges 4–75 - NCT03579875RecruitingPhase 2
Testing an inherited bone marrow transplant approach for rare blood disorders
This Phase 2 study tests a special “T-cell depleted” transplant plan for people with inherited bone marrow failure disorders (Fanconi anemia or T-Beta-thalassemia—or “TBD”). It may help restore healthy blood production while lowering the chance of certain transplant complications.
Minneapolis, MinnesotaAges Up to 65 years - NCT03619850RecruitingPhase 3
Ferumoxytol vs iron sucrose for child kidney anemia
This study compares two IV iron treatments—ferumoxytol and iron sucrose—to treat iron deficiency anemia in children with chronic kidney disease. It aims to see which option works better and is safe, and also to learn how each medicine behaves in the body.
Hollywood, FloridaAges 2–17 - NCT03893045RecruitingPhase 3
Ferumoxytol for iron deficiency anemia in children
This trial tests ferumoxytol, an intravenous iron medicine, to treat iron deficiency anemia in children who cannot take or did not respond well to iron by mouth. It aims to improve blood iron levels and anemia symptoms safely.
Little Rock, ArkansasAges 2–17 - NCT07083960RecruitingPhase 1
Study of OM336 for low blood cell counts caused by immune system
This trial tests a new drug called OM336 for people whose immune system is attacking their own blood cells, causing low counts. It is for those who have already tried at least one treatment that did not work well or stopped working.
Canberra, Australian Capital TerritoryAges 18–75 - NCT04099966RecruitingPhase 2
Stem cell transplant to treat high-risk blood cancers
This trial tests a specialized donor stem cell transplant to treat high-risk problems in the blood and bone marrow, including some cancers and non-cancers. It may help by using donor immune cells designed to better control the disease after transplant.
Valhalla, New YorkAges 1 day–30 years - NCT04268849RecruitingPhase 3
IV vs oral iron after weight-loss surgery
This Phase 3 study compares taking iron through an IV versus by mouth to treat iron-deficiency anemia after Roux-en-Y gastric bypass or sleeve gastrectomy. The goal is to see which method works better and is safer for improving iron levels and blood counts.
Baltimore, MarylandAges 18 years+
Hear when a new Anemia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for anemia?
- Yes. Clin2 currently lists 269 recruiting anemia studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a anemia trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a anemia trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.